erlotinib hydrochloride has been researched along with 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one) | Trials (2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one) | Recent Studies (post-2010) (2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 77 | 0 | 33 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
1 other study(ies) available for erlotinib hydrochloride and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one
| Article | Year |
|---|---|
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |